We relentlessly build on our expertise in cancer immunology and
leading-edge technologies in pursuit of transformative treatments
for cancer patients.
Platform
We have developed proprietary CD3 T cell engaging bispecific antibody technology platform with a more balanced efficacy and safety by the unique CD3 binding arm and long-lasting vaccinal effects by incorporated specific FcγR binding. We also construct the fully-human asymmetric and symmetric IgG bispecific formats for individualized molecule design.